Interestingly, when MM cells were labeled with both biotinylated isatuximab plus daratumumab, they bound to CD38 in a similar manner, suggesting that they do not compete for the CD38 binding site (Figure 1B). The gene discussed is CD38; the disease is Miyoshi myopathy.